Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (22282)	6/16/1998 6:37:00 AM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

What other indications does Panretin gel work for, D? I don't know if you have read previous post of mine regarding off label usage of Pan gel, but I have written that I surely hope lgnd knows of some other uses for it, cuz as of yet I don't recall of their being any other. It is my belief that lgnd pursued P-gel for KS cuz it attacks a disease that has been associated with AIDS. The association with a very political disease can only help lgnd get approval but it is still up in the air if P-gel will have any extensive usage outside of KS. Only once the drug is approved and physicians "decide" it's worth while to prescribe it will we ever know just how well the drug will work. My wild desire, besides running naked around the playboy mansion with every playmate of the month of the last five years, is that p-gel will show an indication for acne. look what acne drugs did for MDRX, and their acne meds are nothing new. Just think "LGND's new drug for AIds patients suffering from KS clears up acne. Millions of young teens around the world can now take relief because there is new weapon that cures acne." As much as that might add a few bucks onto ligand's stock price, it would be a tremendous coup if LGND could also show that p-gel effectively cured acne induced RATS The RAT news would make lgnd soar to heights that ENMD could only dream of.